Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: Results of Eastern Cooperative Oncology Group Study E2479

Cancer

Volumn 79, Issue 8, 1997, Pages 1561-1567

  Oken, Martin M ^a,g   Harrington, David P ^b   Abramson, Neil ^c   Kyle, Robert A ^d   Knospe, William ^e   Glick, John H ^f  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Baptist Regional Cancer Institute   (United States)

^d MAYO CLINIC   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g Virginia Piper Cancer Institute   (United States)

Author keywords

chemotherapy; hematologic malignancy; multiple myeloma; plasma cell neoplasms; treatment

Indexed keywords

CYCLOPHOSPHAMIDE; M PROTEIN; MELPHALAN; PREDNISONE; VINCRISTINE;

ACUTE LEUKEMIA; ADULT; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CROSS-OVER STUDIES; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASMS, SECOND PRIMARY; PREDNISONE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0030911847     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1561::AID-CNCR18>3.0.CO;2-W     Document Type: Article

References (22)

1. Alexanian R, Bonnet J, Gehan E, Haut A, Hewlett J, Lane M, et al. Combination therapy for multiple myeloma. Cancer 1972;30:382-9.
2. Oken MM. Multiple myeloma. Med Clin North Am 1984; 68:757-87.
3. Costa G, Engle RL Jr., Schilling A, Carbone P, Kochwa S, Nachman R, et al. Melphalan and prednisone: an effective combination for the treatment of multiple myeloma. Am J Med 1973;54:589-99.
4. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 1979;301:743-8.
5. MacLennan ICM, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet 1992;339:200-5.
6. Oken MM. Standard treatment of multiple myeloma. Mayo Clin Proc 1994;69:781-6.
7. Case DC, Lee BJ, Clarkson BD. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med 1977;63:897-903.
8. Oken MM, Tsiatis A, Abramson N, Glick J. Comparison of standard (MP) with intensive (VBMCP) therapy for the treatment of multiple myeloma. Proc Am Soc Clin Oncol 1984;3:270.
9. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975;36:842-54.
10. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET. Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
11. Mehta CR, Patel NR. A network algorithm for performing Fisher's exact test in rxc contingency tables. J Am Stat Assoc 1983;78:427-34.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
13. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A 1972;135:185-206.
14. Gray RJ. Some diagnostic methods for Cox regression models through hazard smoothing. Biometrics 1990;46:93-102.
15. Cox DR. Regression models and life tables. J Roy Stat Soc B 1972;34:187-220.
16. Oken MM, Greipp PR, Kay NE, Appelbaum FR. Multiple myeloma. In: Hematology 1993: Education Program. American Society of Hematology, St. Louis, December 3-7,1994.Pages 61-74.
17. Salmon SE, Haut A, Bonnett JD, Amare M, Weick JK, Durie BGM, et al. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1983;1:453-61.
18. Durie BGM, Dixon DO, Carter S, Stephens R, Rivkin S, Bonnet J, et al. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1986;4:1227-37.
19. Salmon SE, Tesh D, Crowley J, Saeed S, Finley P, Milder MS, et al. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1990;8:1575-84.
20. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10:334-42.
21. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, et al. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 1991;325:1267-73.
22. Barlogie B, Jagannath S, Vesole D, et al.Autologous and allogeneic transplants for multiple myeloma. Semin Hematol 1995;32:31-44.